one or more of: halo; $-SCF_3$; (C_1-C_6)alkyl, itself optionally substituted with one or more halo; or (C_1-C_6)alkoxy, itself optionally substituted with one or more halo;

$-C(O)-(CH_2)_n-(C_3-C_{10}$-cycloalkyl);

$-C(O)-(CH_2)_n-NR^nR^o$, wherein R^n and R^o are each independently:

hydrogen;

6 to 10 membered aryl, optionally substituted with one or more of: halo; (C_1-C_6)alkyl, itself optionally substituted with one or more halo; or (C_1-C_6)alkoxy, itself optionally substituted with one or more halo; or

$-C(O)-(CH_2)_n-O-(CH_2)_n-$(6 to 10 membered aryl);

R^{19} is: hydrogen; $-(CH_2)_nOH$; phenyl; $-O-(C_1-C_6)$alkyl; or (C_1-C_6)alkyl, optionally substituted with one or more halo;


R^{20} is: hydrogen; or (C_1-C_6)alkyl, optionally substituted with one or more halo; and

n is 0, 1, or 2.

9. The compound of claim 8, wherein R^{19} is hydrogen or methyl.

10. The compound of claim 8, wherein R^{20} is hydrogen.

~~11. A compound of formula (VII):~~



~~(VII),~~

~~or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:~~

~~R^{21} is hydrogen;~~


~~two of R^{22}-R^{24} together form a 5 to 6 membered ring, optionally substituted with one or more of: halo; (C_1-C_6)alkyl, optionally substituted with one or more halo; and (C_1-C_6)alkoxy, optionally substituted with one or more halo;~~

~~R^{25} is: hydrogen; $-(CH_2)_nOH$; phenyl; $-O-(C_1-C_6)$alkyl; or (C_1-C_6)alkyl, optionally substituted with one or more halo;~~

~~R^{26} is: hydrogen; or (C_1-C_6)alkyl, optionally substituted with one or more halo; and~~

~~n is 0, 1, or 2.~~

~~12. The compound of claim 11, which is:~~



~~or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.~~

~~13~~11. A pharmaceutical composition comprising a compound of any of claims ~~1-12~~1-10, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

~~14~~12. Use of a compound of any of claims ~~1-12~~1-10, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in the manufacture of a medicament for treating, managing or preventing a disease or disorder wherein the disease or disorder is cancer~~, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFα related disorder~~; endometriosis; heart failure; periodontis; gingivitis; pain; atrophic macular degeneration; exudative macular degeneration; age-related maculopathy (ARM); choroidal neovascularisation (CNVM); retinal pigment epithelium detachment (PED); atrophy of retinal pigment epithelium (RPE); mesothelioma; asbestosis; malignant pleural effusion; benign exudative effusion; pleural plaques; pleural calcification; diffuse pleural thickening; rounded atelectasis; fibrotic masses; lung cancer; atherosclerosis; restenosis after vascular intervention; dysfunctional sleep; snoring; sleep apnea; insomnia; narcolepsy; restless leg syndrome; sleep terrors; sleep walking; sleep eating; hemoglobinopathy; sickle cell anemia; endotoxemia or toxic shock syndrome; adult respiratory distress syndrome; arthritis; hypercalcemia; Graft versus Host Reaction; cerebral malaria; inflammation; tumor growth; chronic pulmonary inflammatory diseases; reperfusion injury; myocardial infarction; stroke; circulatory shock; Crohn's disease; HIV infection and AIDS; rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; psoriatic arthritis; septic shock; wasting; ulcerative colitis; multiple sclerosis; systemic lupus; erythromatosis; ENL in leprosy; sepsis; hemodynamic shock and sepsis syndrome; post ischemic reperfusion injury; malaria; meningitis, psoriasis; congestive heart failure; fibrotic disease; cachexia; graft rejection; asthma; hyperoxic alveolar injury; viral conjunctivitis; or atopic dermatitis.